SVF
Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Knockout of E2F1 Inhibits Adipose Stem Cell Proliferation and Differentiation in Fat Transplantation by Repressing Peroxisome Proliferator-Activated Receptor Gamma Expression.

Yang C., Wu Y., Yi Z., Zeng N., Ren Y., Xu Y.

Animal Study on Facial Rejuvenation, published in Transplant Proc (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Transplant Proc (2020)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
32482448
DOI
10.1016/j.transproceed.2020.02.151
Citations
1

Abstract (original English)

Adipose-derived stem cells (ADSCs) possess pluripotent differentiation potential and self-replication ability, which is highly significant in the field of tissue engineering. Cell-assisted lipotransfer (CAL) with ADSCs benefits fat survival. In this study, we focus on the effect of transcription factor E2F1 during CAL. The wild-type (WT) ADSCs were mixed with WT adipocytes, and the E2F1 -/- ADSCs were mixed with E2F1 -/- adipocytes. Then 2 cell mixtures were inoculated on the back 2 sides of E2F1 -/- mice, respectively denoted as the WT group (WT ADSCs + WT adipose cells) and E2F1 -/- group (E2F1 -/- ADSCs + E2F1 -/- adipose cells). At week 4, the fat graft was heavier in the WT group, with less necrotic area, more survival of mature adipocytes, and more proliferating ADSCs, compared with the E2F1 -/- group. More capillaries were transformed from ADSCs in the WT group than in the E2F1 -/- group. The in vitro protein levels of peroxisome proliferator-activated receptor gamma (PPAR-γ) were higher in WT ADSCs than in E2F1 -/- ADSCs. Therefore, these findings suggest that knockout of E2F1 could affect ADSCs to inhibit the survival of fat grafts by downregulating PPAR-γ expression.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipocytesAnimalsCell DifferentiationCell ProliferationCell SurvivalCells, CulturedE2F1 Transcription FactorMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMice
Facial Rejuvenation
View on PubMedDOI

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

View all: topic “knockout e2f1 inhibits”View all: author yangView all: year 2020

Related research